Trials / Completed
CompletedNCT01788228
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) | 2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits. |
Timeline
- Start date
- 2013-03-22
- Primary completion
- 2014-03-27
- Completion
- 2015-02-25
- First posted
- 2013-02-11
- Last updated
- 2020-06-23
- Results posted
- 2015-04-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01788228. Inclusion in this directory is not an endorsement.